Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast.
For the week ending September 4, 2020, John Mandrola, MD comments on the following news and features stories.
The big news in the United States is how the FDA will handle the coming vaccines. The worry is that a vaccine will be released without proper trial data. Politics is in the mix. Everyone has probably heard how FDA commissioner Stephen Hahn misrepresented the results of the observational trial on convalescent plasma use in COVID-19 patients.
He claimed that a 35% relative risk reduction was equivalent to saving 35 lives out of 100 patients treated, which is actually a 35% absolute risk reduction. Thats a big error for a medical student, never mind the head of the FDA.
People suggested this error may have been politically motivated. Hahn apologized publicly the next day. But Medscape editor-in-chief Eric Topol was not impressed. Topol has penned a remarkable letter to Dr. Hahn: Dear Commissioner Hahn: Tell the Truth or Resign. In an era when tone is heavily policed, Topols plain-speak is truly stunning. He lays out Hahns mistakes, and gives five reasons why Hahns apology was insufficient.
I lead the podcast with this because the main thrust of TWIC is the evaluation of clinical science. And now, as we get ready to adjudicate COVID vaccines, the matter of trust in scientists and regulators could not be more vital.
My colleagues at theheart.org | Medscape Cardiology have great coverage of the ESC 2020 Congress. Read it. In 20 minutes, I can only hit the highlights.
Two studies presented as hot-line trials at ESC strengthened the evidence for the sodium glucose cotransporter 2 (SGLT2) inhibitors. Recall that SGLT2 inhibitors reduce renal tubular glucose reabsorption, producing a reduction in blood glucose without stimulating insulin release. Other benefits include reducing blood pressure and weight.
EMPEROR-Reduced enrolled about 3700 patients with heart failure with reduced ejection fraction (HFrEF), about half of them with diabetes. Participants were randomly assigned to receive empagliflozin 10 mg daily or placebo. The primary endpoints were cardiovascular (CV) death and heart failure hospitalization (HFH). In sum, patients in the empagliflozin arm had a 31% reduction in HFH and an 8% reduction in CV death.
Empagliflozin had statistically significant effect on renal outcomes (not seen in DAPA-HF) and had beneficial effects on the primary endpoints in all subgroups, including the group taking angiotensin receptor neprilysin inhibitor (ARNi) drugs.
The big discussion point is that the primary endpoint was driven by the non-fatal outcome of HFH. The confidence interval for CV death was 0.75-1.12, so some might say non-significant. This contrasts with DAPA-HF where CV death was 18% lower and the CI did not include 1.
DAPA-CKD was primarily a renal outcomes trial, but there were interesting CV secondary outcomes as well. About 4300 patients with CKD and albuminuria were randomly assigned to receive dapagliflozin vs placebo. The primary endpoint was a composite of 50% decline in glomerular filtration rate, end stage kidney disease, renal death, or CV death.
There were 197 primary endpoint events in the dapagliflozin arm vs 312 in the placebo arm, for a 39% relative risk reduction and about 5% absolute risk reduction with dapagliflozin. This reduction was seen in diabetics and non-diabetics. Secondary endpoints of CV death and HFH, as well as all-cause mortality were also lower in dapagliflozin arm.
The effects of SGLT2 inhibitors are consistent across trials; the CV death reduction and overall death signals are favorable, renal preservation looks consistent, side effects are not awful, and the benefit is seen in non-diabetics and diabetics alike.
I think we have a new class of drugs in cardiology.
The surprise of ESC came with favorable results from a digoxin trial. Dipak Kotecha from the University of Birmingham, England, presented results of the Rate AF trial comparing digoxin vs bisoprolol in patients with permanent atrial fibrillation (AF). Kudos to the research team for studying permanent AF. Most of the research goes to paroxysmal AF and persistent AF, but probably half of the millions of patients with AF have permanent AF.
About 160 patients were randomly assigned to either digoxin or bisoprolol.
The primary endpoint included patient-reported quality of life measures. Secondary endpoints included BNP, ejection fraction, and clinical events.
Sit down for the results: Heart rate responses were identical. Physical function at 6 monthsthe primary endpoint was not significantly different in either group. More than 50% of patients receiving digoxin compared with less than 10% on -blockers improved more than two classes in themodified European Heart Rhythm Association (EHRA)symptom score (mEHRA for AF is similar to New York Heart Association [NYHA] for heart failure and ranges from I to IV).
Over 6 to 12 months, improvement in NYHA class and NTproBNP level was significantly greater in the digoxin arm. Left ventricular ejection fraction remained unchanged in both arms. While the trial was not powered for clinical events, there were fewer all-cause deaths (4 vs 7), cardiovascular deaths (3 vs 15), and adverse events (29 vs 142) in the digoxin arm.
While I love this trial, there are reasons for serious caution: This was an oral presentation. The details of the paper will be key. How did they use digoxin; did they do drug levels? Also, digoxin use has a narrow therapeutic window, clinicians have to consider drug-drug interactions and renal clearance and these things are easier to do in a trial than in a busy practice. Another reason for caution was the open-label nature of the trial. Beta bockers have strong nocebo effects and this may bias the self-assessment of physical functioning.
The authors wrote in their protocol paper that RATE-AF trial will also act as a feasibility study to plan a future, event-driven clinical trial exploring the impact of different rate control strategies on cardiovascular events and unplanned hospital admissions.
Besides the stunning results, another reason this trial excites me is the digoxin backstory: namely, that digoxin had been unfairly made into a toxic drug. I say unfairly because the studies that caused its fall from favor were nonrandomized observational studies. RATE-AF shows again the power of randomization. In addition to the specifics of AF care, it again humbles us regarding the temptation to make causal claims from nonrandomized observational data.
The EAST AFNET 4 trial, which henceforth I will refer simply as EAST, asked a highly relevant question: would an early-rhythm control approach to patients with AF improve clinical outcomes vs a conventional strategy of rate control. The background is that early rhythm control might prevent unfavorable atrial (and ventricular) remodeling and that could cause better CV outcomes.
On the other hand, rhythm control is complicated. AF ablation is inelegant and comes with a finite risk for complications. Antiarrhythmic drugs are super-inelegant and surely come with adverse effects. That is why you need an RCT. The highly pragmatic study overflows with lessons.
This was a multicenter trial that included a wide variety of non-permanent AF types. New AF, paroxysmal AF, persistent AF, and asymptomatic AF were all substantially represented. About 2800 patients were randomly assigned to early rhythm control vs usual care. Importantly the trial was open-label, though outcomes were adjudged in a blinded fashion. The authors chose co-primary efficacy endpoints: the first was a composite of cardiovascular (CV) death, stroke, hospital admission for heart failure or acute coronary syndrome, and the second was days spent in the hospital.
The primary safety outcome was a composite of death, stroke, or serious adverse events related to rhythm control. The overlap of having stroke and death in both efficacy and safety outcomes is a problem. Stay tuned for that.
About 90% of both groups continued to receive oral anticoagulant therapy throughout the trial. And early rhythm control was indeed earlypatients were randomized about a month after their diagnosis. EAST-AFNET 4 was stopped for efficacy after a median of 5 years.
A primary outcome event occurred in 249 patients in the early care arm vs 316 patients in the usual care arm. The hazard ratio was 0.79, with a confidence interval of 0.66 to 0.94 (P=.005). The absolute risk reduction was 1.1% per 100 person-years and 3% over 5 years. Each component of the primary outcome was numerically lower in the early care arm. In a trial of almost 2800 patients, there were 27 fewer CV deaths in the early care group (1.0% vs 1.3% per 100 patient-years). The average days spent in hospital were similar in both groups. The overall primary safety outcome did not differ significantly between the two treatment arms.
Here is the problemthe components of the composite diverged. Serious adverse events related to rhythm-control therapy occurred in 4.9% of the patients assigned to early rhythm control and 1.4% of the patients assigned to usual care.
How could the overall outcome then be different? Stroke was lower in the early care arm. But the authors had already used this in the efficacy endpoint. Using it in the safety composite helps dilute the higher rate of serious advents in the early care group. Same story with deaththough it is more complicated. CV death was lower in the early care group and this helped drive the primary efficacy endpoint. Overall death has CV death as a component. If you subtract the number of CV deaths in each group from the overall death, you find non-CV death was 71 and 70 respectively. Thus, by using overall death in the safety outcome you further dilute the serious adverse events in the rhythm-control arm.
There were other concerns: substantial missing data, and that HF and acute coronary syndrome admissions is a potentially biased endpoint in an open label trial. External validity is relevant because these were expert centers. In less expert centers, serious adverse events from antiarrhythmic drugs or ablation might be much higher.
In sum, early rhythm-control strategy may improve outcomes compared with a strategy of rate control. But these potential gains come with a risk for serious adverse events. EAST should not be oversimplified to mean "use more antiarrhythmic drugs" or "do more ablation." Instead, the nuance and tradeoffs in these findings strongly support a shared understanding between clinician and patient.
Read more from the original source:
Sep 4 2020 This Week in Cardiology - Medscape
- Managing Right Ventricular Failure in PAH: An Algorithmic Approach | Advances in ... - April 13th, 2018 [April 13th, 2018]
- What Is the Ejection Fraction? - Verywell Health - May 12th, 2018 [May 12th, 2018]
- Ventricular septal defect - Wikipedia - June 21st, 2018 [June 21st, 2018]
- Heart Failure Medication: Beta-Blockers, Alpha Activity ... - July 7th, 2018 [July 7th, 2018]
- Acute Management of Pulmonary Embolism - American College ... - July 17th, 2018 [July 17th, 2018]
- Ventricular Remodeling | Profiles RNS - July 24th, 2018 [July 24th, 2018]
- Left ventricular hypertrophy - Wikipedia - August 20th, 2018 [August 20th, 2018]
- Ventricular Remodeling Surgery (SVR) - September 24th, 2018 [September 24th, 2018]
- Left Ventricular Remodeling in Heart Failure | JACC ... - November 25th, 2018 [November 25th, 2018]
- Ventricular dysfunction in heart failure - Britannica.com - December 25th, 2018 [December 25th, 2018]
- TIMI Study Group - LEADERSHIP - January 31st, 2019 [January 31st, 2019]
- Ventricular Remodeling Procedure | Main Line Health ... - February 24th, 2019 [February 24th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS) - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Reviewing Aeterna Zentaris Inc. (AEZS)'s and BioLineRx Ltd. (NASDAQ:BLRX)'s results - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Karuna Therapeutics Inc. (KRTX) and BioLineRx Ltd. (NASDAQ:BLRX) Comparing side by side - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Arbutus Biopharma Corporation (ABUS)'s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX) - The EN Herald - September 18th, 2019 [September 18th, 2019]
- Cardiac Dimensions touts Carillon TMVR study - Mass Device - September 18th, 2019 [September 18th, 2019]
- New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF - TCTMD - September 18th, 2019 [September 18th, 2019]
- Cardiac Restoration Systems Market Will Make a Huge Impact in Near Future - Wolf Mirror - September 18th, 2019 [September 18th, 2019]
- Reduce Fmr Study Shows Cardiac Dimensions' Carillon System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure - TCTMD - September 18th, 2019 [September 18th, 2019]
- Heart Failure Society of America 2019: Virtual Visits, Spironolactone Issues, and Reasons to Worry - DocWire News - September 18th, 2019 [September 18th, 2019]
- LV Reverse Remodeling Not Improved by SGLT-2 Inhibitor - DocWire News - September 18th, 2019 [September 18th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Soligenix Inc. (NASDAQ:SNGX) - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) Could Burn Your Long Portfolio After More Shorts - The MAK Daily - September 22nd, 2019 [September 22nd, 2019]
- Reviewing BioLineRx Ltd. (BLRX)'s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)'s results - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Comparison of Protalix BioTherapeutics Inc. (PLX) and BioLineRx Ltd. (NASDAQ:BLRX) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Edge Therapeutics Inc. (:) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Cyanotech Corporation (NASDAQ:CYAN) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for... - November 7th, 2019 [November 7th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) - The Broch Herald - December 3rd, 2019 [December 3rd, 2019]
- Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT - Yahoo Finance - December 3rd, 2019 [December 3rd, 2019]
- Cardiac Restoration Systems Market: Key Growth Factors and Industry Analysis 2018 - 2028 - The Market Expedition - December 3rd, 2019 [December 3rd, 2019]
- Velocity Transfer Function In The Right Pulmonary Artery And Impaired | COPD - Dove Medical Press - December 3rd, 2019 [December 3rd, 2019]
- 3 Stocks to Buy Ahead of the Next Market Crash - The Motley Fool - December 3rd, 2019 [December 3rd, 2019]
- Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival - TCTMD - December 3rd, 2019 [December 3rd, 2019]
- Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy - AJMC.com Managed Markets Network - December 4th, 2019 [December 4th, 2019]
- BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System - Yahoo Finance - December 4th, 2019 [December 4th, 2019]
- Cardiac Restoration Systems Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2055 2017 2025 - Weekly News Times - December 13th, 2019 [December 13th, 2019]
- The Outer Line: The impact of endurance training on the cardiac health of women - VeloNews - December 13th, 2019 [December 13th, 2019]
- Contrasting of Insmed Incorporated (INSM) and BioLineRx Ltd. (NASDAQ:BLRX) - The CoinGlobalist - December 16th, 2019 [December 16th, 2019]
- CARDIAC RESTORATION SYSTEMS MARKET ANALYSIS TRENDS, GROWTH OPPORTUNITIES, SIZE, TYPE, DYNAMIC DEMAND AND DRIVES WITH FORECASTS TO 2028 - Voice of... - January 13th, 2020 [January 13th, 2020]
- Early Expressed Circulating Long Noncoding RNA CHAST is Associated with Cardiac Contractile Function in Patients with Acute Myocardial Infarction -... - January 13th, 2020 [January 13th, 2020]
- Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone - DocWire News - January 23rd, 2020 [January 23rd, 2020]
- Increased Long-Term Risk for Venous Thromboembolism After Heart Failure - The Cardiology Advisor - January 23rd, 2020 [January 23rd, 2020]
- Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity - Science Advances - February 1st, 2020 [February 1st, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - The Cardiology Advisor - February 1st, 2020 [February 1st, 2020]
- New Data Confirms Cardiac Dimensions' Carillon System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation -... - February 26th, 2020 [February 26th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Yahoo Finance - March 5th, 2020 [March 5th, 2020]
- Relationship between histopathological features of aspirated thrombi and long-term left ventricular function in patients with ST-segment elevation... - March 15th, 2020 [March 15th, 2020]
- FierceMedTech Names BioVentrix as One of Its "Fierce 15" Companies of 2019 - Yahoo Finance - March 15th, 2020 [March 15th, 2020]
- Causes and Prevention of Ventricular Remodeling After MI ... - March 16th, 2020 [March 16th, 2020]
- Left Ventricular Remodelling - ECR Journal - April 23rd, 2020 [April 23rd, 2020]
- Cardiac Restoration Systems Market to Make Great Impact in Near Future by 2026 - The Canton Independent Sentinel - June 12th, 2020 [June 12th, 2020]
- Multi-Society Guidelines on the Use of Multimodality CV Imaging in Competitive Athletes - The Cardiology Advisor - June 12th, 2020 [June 12th, 2020]
- Chronic PDE5i Treatment Found to Improve Cardiac Remodeling in Men, but Not Women, With Diabetic Cardiomyopathy - Endocrinology Advisor - June 12th, 2020 [June 12th, 2020]
- Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Thoracic Society 2020... - June 23rd, 2020 [June 23rd, 2020]
- American Heart Association and Barth Syndrome Foundation Partner to Address Rare Disease - PR Web - August 29th, 2020 [August 29th, 2020]
- The Association of Cardio-Ankle Vascular Index (CAVI) with Biatrial Remodeling in Atrial Fibrillation - DocWire News - September 3rd, 2020 [September 3rd, 2020]
- Cardiac Dimensions Announces Australian Therapeutic Goods Administration's Approval of the Carillon System for the Treatment of Functional Mitral... - September 3rd, 2020 [September 3rd, 2020]
- Emerging treatment helps reverse heart failure in some patients - Science Codex - October 27th, 2020 [October 27th, 2020]
- GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial - PRNewswire - October 27th, 2020 [October 27th, 2020]
- North America to Outshine the Global Slowdown in Cardiac Restoration Systems market between 2020 and 2030 - The Think Curiouser - November 12th, 2020 [November 12th, 2020]
- Age-Related Development of Cardiac Remodeling and Dysfunction in Young Black and White Adults: the Coronary Artery Risk Development in Young Adults... - November 25th, 2020 [November 25th, 2020]
- Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin - Science Advances - January 13th, 2021 [January 13th, 2021]
- Longer Survival Seen in Heart Failure Stabilized Via Cardiac Resynchronization Therapy - The Cardiology Advisor - April 13th, 2021 [April 13th, 2021]
- Cardiac Dimensions Welcomes Robert White to its Board of Directors - PRNewswire - April 13th, 2021 [April 13th, 2021]
- [Full text] SIRT1 is Required for Exercise-Induced Beneficial Effects on Myocardia | JIR - Dove Medical Press - April 13th, 2021 [April 13th, 2021]
- Role of Pyroptosis in Diabetes and Its Therapeutic Implications | JIR - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Are you at risk for sudden death, and can it be prevented? - Jamaica Observer - May 25th, 2021 [May 25th, 2021]
- Does a plant-based diet improve cardiac function? Here's the answer - Hindustan Times - June 21st, 2021 [June 21st, 2021]
- Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI - AJMC.com Managed Markets Network - November 5th, 2021 [November 5th, 2021]
- Higher BP, LV Changes Seen in Children Conceived by ART - Medscape - November 5th, 2021 [November 5th, 2021]
- Regional Heterogeneity in Determinants of Atrial Matrix Remodeling and Association with Atrial Fibrillation Vulnerability Post-Myocardial Infarction -... - January 26th, 2022 [January 26th, 2022]
- 4 promising heart failure therapies interventional cardiologists should keep an eye on - Cardiovascular Business - May 7th, 2022 [May 7th, 2022]
- LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - Yahoo Finance - May 7th, 2022 [May 7th, 2022]
- Ventricular structure and function in hypertensive patients | IJGM - Dove Medical Press - May 7th, 2022 [May 7th, 2022]
- Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction:... - May 7th, 2022 [May 7th, 2022]
- Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study - Business Wire - September 12th, 2022 [September 12th, 2022]